

Int'l App. No.: PCT/GB00/01521
Int'l Filing Date: 19 April 2000

12. (Amended) A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of hydrate according to claim 1 to a human or non-human mammal in need thereof.


REMARKS

The above-identified application is being entered into the National Phase from PCT application No. PCT/GB00/01521.

Applicants have amended the claims to put them in conformity with U.S. practice. Attached hereto is a marked up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

No new matter has been introduced.

Respectfully submitted,



Yuriy P. Stercho, Ph.D.
Attorney for Applicants
Registration No. 33,797

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5018
Facsimile (610) 270-5073
n\yps\response\P32285\preamd.

Int'l App. No.: PCT/GB00/01521
Int'l Filing Date: 19 April 2000

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

An abstract has been added.

In the Claims:

Claims 9-11 have been canceled.

1. (Amended) 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, hydrochloride dihydrate [characterized in that it] comprising:

(ii) provides an infrared spectrum containing peaks at 3392, 2739, 1751, 1325 and 713 cm^{-1} ; and/or

(ii) provides an X-ray powder diffraction (XRPD) pattern containing peaks at 9.1, 12.0, 15.7, 16.3 and 19.8 $^{\circ}2\theta$.

3. (Amended) A hydrate according to claim 1 [or claim 2], which provides an X-ray powder diffraction (XRPD) pattern substantially in accordance with Figure II.

4. (Amended) A hydrate according to [any one of] claim[s] 1 [to 3], in isolated form.

5. (Amended) A hydrate according to [any one of] claim[s] 1 [to 4], in pure form.

6. (Amended) A hydrate according to [any one of] claim[s] 1 [to 5], in crystalline form.

12. (Amended) A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of hydrate according to claim 1 to a human or non-human mammal in need thereof.

202205361001